| GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease R Loomba, Z Kayali, M Noureddin, P Ruane, EJ Lawitz, M Bennett, ... Gastroenterology 155 (5), 1463-1473. e6, 2018 | 300 | 2018 |
| Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials QM Anstee, EJ Lawitz, N Alkhouri, VWS Wong, M Romero‐Gomez, ... Hepatology 70 (5), 1521-1530, 2019 | 232 | 2019 |
| Performance of noninvasive tests of fibrosis among Asians, Hispanic, and non-Hispanic whites in the stellar trials VWS Wong, WY Tak, GBB Goh, PN Cheng, EJ Lawitz, ZM Younossi, ... Clinical Gastroenterology and Hepatology 21 (1), 90-102. e6, 2023 | 13 | 2023 |
| Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients EJ Lawitz, KW Li, E Nyangau, TJ Field, JC Chuang, A Billin, L Wang, ... Journal of lipid research 63 (9), 2022 | 9 | 2022 |
| GS-0976, a liver-targeted acetyl-coa carboxylase (ACC) inhibitor, reduces plasma acylcarnitines in patients with nonalcoholic steatohepatitis (NASH) MR Charlton, M Lai, M Noureddin, JM Tarrant, L Wang, T Nguyen, ... Hepatology 68, 992A-993A, 2018 | 3 | 2018 |
| Characterization of changes in lipoprotein profiles of patients with nonalcoholic steatohepatitis treated with the acetyl-CoA carboxylase inhibitor GS-0976 P Mantry, Z Kayali, M Noureddin, P Ruane, B Mccolgan, J Tarrant, ... Journal of Hepatology 68, S583-S584, 2018 | 1 | 2018 |
| Prediction of fibrosis improvement in patients with advanced fibrosis due to NASH using a machine learning approach: Unravelling the placebo response A Sanyal, T Nguyen, L Wang, Y Xiao, C Jia, R Xu, S Djedjos, ... Journal of Hepatology 68, S97, 2018 | 1 | 2018 |
| Group Sequential Design With Change of Endpoint L Wang, Q Li, Z Li, A Kaur Statistics in Biopharmaceutical Research 9 (4), 338-346, 2017 | 1 | 2017 |
| Some topics on model-based clustering L Wang 2000-2019-CSU Theses and Dissertations, 2016 | 1 | 2016 |
| Serum bile acids are markedly elevated in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH) A Sanyal, S Harrison, M Charlton, S Caldwell, J Chuang, L Wang, G Chen, ... Journal of Hepatology 68, S550-S551, 2018 | | 2018 |
